Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study
Highly competitive grant award provides significant non-dilutive funding to support Phase 2 development of MT-601 in CAR-relapsed lymphoma CPRIT award builds on encouraging Phase 1 clinical results, with additional patient data and updated response durability data expected later…
